ENTA
Price
$8.85
Change
-$0.04 (-0.45%)
Updated
Sep 5 closing price
Capitalization
189.19M
71 days until earnings call
FATE
Price
$1.01
Change
+$0.04 (+4.12%)
Updated
Sep 5 closing price
Capitalization
116.48M
53 days until earnings call
Interact to see
Advertisement

ENTA vs FATE

Header iconENTA vs FATE Comparison
Open Charts ENTA vs FATEBanner chart's image
Enanta Pharmaceuticals
Price$8.85
Change-$0.04 (-0.45%)
Volume$103.8K
Capitalization189.19M
Fate Therapeutics
Price$1.01
Change+$0.04 (+4.12%)
Volume$1.66M
Capitalization116.48M
ENTA vs FATE Comparison Chart in %
Loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTA vs. FATE commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Hold and FATE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (ENTA: $8.85 vs. FATE: $1.01)
Brand notoriety: ENTA and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 62% vs. FATE: 115%
Market capitalization -- ENTA: $189.19M vs. FATE: $116.48M
ENTA [@Biotechnology] is valued at $189.19M. FATE’s [@Biotechnology] market capitalization is $116.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, ENTA is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 7 TA indicator(s) are bullish while FATE’s TA Score has 4 bullish TA indicator(s).

  • ENTA’s TA Score: 7 bullish, 4 bearish.
  • FATE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than FATE.

Price Growth

ENTA (@Biotechnology) experienced а +5.36% price change this week, while FATE (@Biotechnology) price change was -2.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

ENTA is expected to report earnings on Nov 17, 2025.

FATE is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ENTA($189M) has a higher market cap than FATE($116M). ENTA YTD gains are higher at: 53.913 vs. FATE (-38.788). ENTA has higher annual earnings (EBITDA): -82.41M vs. FATE (-161.6M). FATE has more cash in the bank: 223M vs. ENTA (204M). ENTA has less debt than FATE: ENTA (58M) vs FATE (81.3M). ENTA has higher revenues than FATE: ENTA (64.8M) vs FATE (8.47M).
ENTAFATEENTA / FATE
Capitalization189M116M163%
EBITDA-82.41M-161.6M51%
Gain YTD53.913-38.788-139%
P/E RatioN/AN/A-
Revenue64.8M8.47M765%
Total Cash204M223M91%
Total Debt58M81.3M71%
FUNDAMENTALS RATINGS
ENTA vs FATE: Fundamental Ratings
ENTA
FATE
OUTLOOK RATING
1..100
8764
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4487
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (13) in the Biotechnology industry is significantly better than the same rating for ENTA (95). This means that FATE’s stock grew significantly faster than ENTA’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ENTA (100). This means that FATE’s stock grew similarly to ENTA’s over the last 12 months.

FATE's SMR Rating (98) in the Biotechnology industry is in the same range as ENTA (98). This means that FATE’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's Price Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for FATE (87). This means that ENTA’s stock grew somewhat faster than FATE’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for FATE (100). This means that ENTA’s stock grew significantly faster than FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTAFATE
RSI
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
64%
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 19 days ago
71%
Bullish Trend 12 days ago
86%
Declines
ODDS (%)
Bearish Trend 12 days ago
83%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
78%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 4 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SSHPF0.220.03
+14.03%
Vow ASA
BUHPF4.85N/A
N/A
Bumrungrad Hospital Public Co., Ltd.
NGRC0.03N/A
N/A
National Graphite Corp.
NGRRF58.49N/A
N/A
Nagarro SE
SDZXF62.16N/A
N/A
Sandoz Group AG

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with ADCT. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then ADCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-0.45%
ADCT - ENTA
35%
Loosely correlated
+4.12%
VRDN - ENTA
35%
Loosely correlated
+0.43%
AKRO - ENTA
34%
Loosely correlated
+1.57%
FATE - ENTA
34%
Loosely correlated
+3.81%
BEAM - ENTA
34%
Loosely correlated
+12.62%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with RXRX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+3.81%
RXRX - FATE
53%
Loosely correlated
+1.99%
CRBU - FATE
52%
Loosely correlated
+1.08%
MGNX - FATE
52%
Loosely correlated
+3.09%
ALLO - FATE
51%
Loosely correlated
+3.60%
NTLA - FATE
50%
Loosely correlated
+3.79%
More